2023年美国国立综合癌症网络(NCCN)《骨髓增生异常综合征临床实践指南》(第1版)解读  

Interpretation of clinical practice guidelines for myelodysplastic syndrome(version 1,2023)of National Comprehensive Cancer Nerwork(NCCN)

作　　者：宋陆茜[1] 常春康[1] SONG Luqian;CHANG Chunkang(Department of Hematology,Shanghai Sixth people’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200233,China)

机构地区：[1]上海交通大学医学院附属第六人民医院血液科,上海200233

出　　处：《诊断学理论与实践》2023年第2期116-120,共5页Journal of Diagnostics Concepts & Practice

基　　金：国家自然科学基金(82070129);SHDC临床研究计划(SHDC 2020 CR 6004);优秀医学学科带头人项目(2019LJ16)。

摘　　要：骨髓增生异常综合征(myelodysplastic syndrome,MDS)是血液系统中较为常见的一组髓系恶性克隆性疾病。不同分型的MDS患者,其临床表现及自然病程各异,加上历史上不同分型系统及版本的迭代,对其诊断、分型及治疗方案选择造成了一定困扰。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)于2022年9月发布了2023年第1版NCCN的MDS临床实践指南。该指南是基于高级别循证医学证据和最新研究进展而制定的MDS临床实践标准,其受到全球临床医师的广泛关注。目前,我国许多临床医师对MDS的认识不足,与国际MDS诊断及治疗水平间仍存在一定的差距。本文将对该指南发布内容进行解读,并与既往相关指南比较。Myelodysplastic syndrome(MDS)is a diverse and common group of myeloid malignant clonal diseases in the hematologic system,with different classification and grouping,clinical manifestations and natural course,and the itera-tion of different classification systems and versions in history,resulting distress in the correct diagnosis,classification and treatment options.The National Comprehensive Cancer Network(NCCN)released the first version(2023)of Clinical Prac-tice Guidelines for MDS in September 2022.The guideline is based on the clinical practice and standards of high-level evi-dence and the latest research progress,and its attracts wide attention from clinicians worldwide.Currently,many clinicians in China have insufficient understanding of MDS,and there is stll a certain gap with the international diagnosis and treat-ment level of MDS.This paper interprets the content of the new guidelines,and compares it with the previous guidelines,in order to provide a reference for the standardized diagnosis and treatment of MDS at the current stage in China.

关 键 词：骨髓增生异常综合征 诊断 预后 指南 解读 

分 类 号：R733.3[医药卫生—肿瘤]